Clinical trials
Neoplasm Metastasis trials in Belgium with no applicable phase
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
15 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2006 | 1 |
| 2007 | 1 |
| 2011 | 1 |
| 2014 | 1 |
| 2015 | 1 |
| 2016 | 1 |
| 2017 | 2 |
| 2018 | 1 |
| 2019 | 1 |
| 2020 | 1 |
| 2021 | 2 |
| 2022 | 1 |
| 2025 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 7 |
| Unknown status | 5 |
| Recruiting | 2 |
| Not yet recruiting | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Cancer Research Antwerp | 2 |
| Jules Bordet Institute | 2 |
| The Belgian Society of Medical Oncology | 2 |
| Boston Scientific Corporation | 1 |
| Cliniques universitaires Saint-Luc- Université Catholique de Louvain | 1 |
| Fondazione Poliambulanza Istituto Ospedaliero | 1 |
| OncoSil Medical Limited | 1 |
| Terumo Europe N.V. | 1 |
| Universitair Ziekenhuis Brussel | 1 |
| Universitaire Ziekenhuizen KU Leuven | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Neoplasm Metastasis | 15 |
| Breast Neoplasms | 2 |
| Prostatic Neoplasms | 2 |
| Brain Neoplasms | 1 |
| Colonic Neoplasms | 1 |
| Colorectal Neoplasms | 1 |
| Lymphedema | 1 |
| Neoplasms | 1 |
| Pancreatic Neoplasms | 1 |
| Urinary Incontinence, Stress | 1 |
Trials
Showing 1 to 15 of 15. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.